Yusuke Kohno
Head of Supply Chain Development Alpha Fusion Inc.
Mr. Kohno is a serial entrepreneur with over 20 years of experience in biotech and CDMO businesses. Early in his career, he co-founded a company focused on peptide drugs and PROTACs, serving as a CXO. Prior to joining Alpha Fusion, he played a key role in launching and scaling ARCALIS Inc., a CDMO specializing in mRNA therapeutics from active ingredients to final formulations. At Alpha Fusion, he now leads CMC development for At-211 radiopharmaceuticals and oversees the investigational drug supply chain. Mr. Kohno holds a B.S. and M.S. in Organic Chemistry from Tokyo University of Agriculture and Technology.
Seminars
Wednesday 22nd July 2026
Panel Discussion: Investigating Various Isotope Half-Lives as a Limiting Factor in Radiotherapeutic Scalability, Quality Control & Patient Access
11:00 am
- Defining how isotope half-life constrains manufacturing timelines, QC strategy, and logistics
- Contrasting mature distribution models for lutetium-177 with emerging requirements for short-lived isotopes such as astatine-211
- Identifying which capabilities in licensing, training, automation, and packaging can be leveraged across isotope classes
